Alkermes plc
ALKS
주식 순위
#2726
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
주가
$41.39
마지막 동기화: 2026-10-16
시가총액
$6.94B
변동 (1일)
3.22%
변동 (1년)
36.78%
국가
IE
거래 Alkermes plc (ALKS)
카테고리
Healthcare
Alkermes plc (ALKS)의 EPS
June 2026 기준 EPS TTM: $0.40
Alkermes plc의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $0.40입니다. 2023년 말에는 회사의 EPS가 $2.14였으며, 이는 2022년의 EPS $-0.97와 증가입니다.
Alkermes plc의 EPS 기록 (2000 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $0.40 | -81.98% |
| 2024 | $2.22 | 3.74% |
| 2023 | $2.14 | -320.62% |
| 2022 | $-0.97 | 223.33% |
| 2021 | $-0.30 | -57.14% |
| 2020 | $-0.70 | -44.00% |
| 2019 | $-1.25 | 38.89% |
| 2018 | $-0.90 | -12.62% |
| 2017 | $-1.03 | -25.36% |
| 2016 | $-1.38 | -9.21% |
| 2015 | $-1.52 | 623.81% |
| 2014 | $-0.21 | -210.53% |
| 2013 | $0.19 | 0.00% |
| 2012 | $0.19 | -119.19% |
| 2011 | $-0.99 | 106.25% |
| 2010 | $-0.48 | 14.29% |
| 2009 | $-0.42 | -130.66% |
| 2008 | $1.37 | -17.47% |
| 2007 | $1.66 | 1,560.00% |
| 2006 | $0.10 | 150.00% |
| 2005 | $0.04 | -104.82% |
| 2004 | $-0.83 | -33.60% |
| 2003 | $-1.25 | -26.47% |
| 2002 | $-1.70 | 77.08% |
| 2001 | $-0.96 | 123.26% |
| 2000 | $-0.43 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | 4,230.00% |
US
|
|
| $-7.98 | -2,095.00% |
US
|
|
| $-5.29 | -1,422.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 6,835.00% |
NL
|
